Pulmonary Function Testing System Market Size to Register 4.4% during 2023-2030; Rising Awareness of Early Diagnosis and Technological Innovations of Testing Solutions to Boost Market Growth

The global pulmonary function testing systems market size was valued at USD 152.3 million in 2022 and is projected to reach USD 158.1 million in 2023. The market is expected to touch USD 214.1 million by 2030, exhibiting a CAGR of 4.4% over 2023-2030.

Fortune Business Insights™ presents this information in its latest report titled “Pulmonary Function Testing System Market Size, Share & COVID-19 Impact Analysis, By Type (Portable and Complete), By End-user (Hospitals, Physical Examination (Diagnostic) Centers, Physician Groups (Clinics), and Others), and Regional Forecast, 2023-2030”.

Pulmonary function testing systems carry out a variety of pulmonary function tests, especially in patients suffering from chronic respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. Two types of devices – complete and portable systems - are used by hospitals and medical centers to diagnose various breathing disorders. These systems are undergoing technological advancements to improve their performance and accuracy. This factor is expected to accelerate the pulmonary function testing system market growth.

COVID-19 Pandemic Observed Sluggish Growth in 2020 Owing to Shutdown of Clinics

The impact of COVID-19 outbreak led to reduced demand for Pulmonary Function Testing (PFT) systems as the deployment of these machines decreased at the peak of the pandemic. However, since governments of some countries relaxed lockdown restrictions, many healthcare facilities resumed the use of pulmonary function testing systems along with RT-PCR tests. The global market perceived a slow growth rate of 1.4% in 2020 in comparison with 3.3% in 2019.

Rising Awareness of Early Diagnosis and Technological Innovations of Testing Solutions to Boost Market Growth

Pulmonary function testing systems analyze the functioning of a patient’s lungs in a non-invasive manner. These tests can measure lung volume, capacity, gas exchange, and flow rates and help doctors come up with a variety of treatments for certain lung diseases. Pulmonary function testing machines play a key role in detecting abnormalities in asymptomatic patients at an early stage. This factor, along with technological advancements in testing systems will help the market grow considerably.

PulmOne USA Inc. Partnered with Circassia Pharmaceuticals to Offer NIOX VERO FeNO System

PulmOne USA Inc. announced its partnership with Circassia Pharmaceuticals to deliver the NIOX VERO fractional exhaled nitric oxide (FeNO) airway inflammation measurement system. The system will act as an integrated add-on to PulmOne’s Minibox+ and will be supplied to the current as well as new customers of both the companies. The Minibox+ is a desktop, cabinless device used by primary care physicians and specialists to offer a complete pulmonary function testing to their patients, as suggested by the American Thoracic Society (ATS). Integrating the NIOX VERO system can increase the testing capabilities of the Minibox+, allowing physicians to identify and treat a wider range of respiratory diseases.

Strong Product Portfolio will Help Key Companies Strengthen their Market Presence

This market has a consolidated presence of leading companies that specialize in the manufacturing of pulmonary function testing systems.

MGC Diagnostics Corporation and VYAIRE MEDICAL, INC. captured the largest share of the market as they have a strong portfolio of PFT systems and are focusing on approvals to launch innovative devices in the market.

The growing focus of key companies on introducing these systems in developing nations is expected to solidify their market position during the forecast period. Moreover, companies, such as PulmOne Advanced Medical Devices, are boosting their focus on increasing their product lineup and geographical presence.

Notable Industry Development:

January 2023: CAIRE Inc., a subsidiary of NGK SPARK PLUG CO., LTD., announced the acquisition of MGC Diagnostics Corporation to expand its expertise in pulmonary disease.

List of Key Players Mentioned in the Report:

• ndd Medizintechnik AG (Switzerland)
• COSMED srl (Italy)
• MGC Diagnostics Corporation (U.S.)
• PulmOne Advanced Medical Devices (Israel)
• CHEST M.I., Inc. (Japan)
• VYAIRE MEDICAL, INC. (U.S.)
• KoKo PFT (U.S.)
• Medical Electronic Construction (Belgium)

Further Report Findings:

• North America dominated the pulmonary function testing system market share and may record a strong CAGR during the forecast period due to the rising deployment of portable machines and high use of these devices in clinics and diagnostic centers across the region.
• Asia Pacific is expected to record the fastest CAGR during the analysis timeframe as the awareness regarding the use of pulmonary function tests is increasing among medical professionals in the region.
• The hospitals segment is anticipated to hold the largest share of the market as the number of patients visiting hospitals to get treated for asthma and COPD is increasing. Also, the rising use of complete systems to diagnose various breathing disorders in patients will further boost the segment’s growth.

Table of Segmentation: